AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tonyt who wrote (396)	8/16/1997 9:22:00 PM
From: David Bogdanoff	of 2173

Tonyt; There are many companies working on a diabetes therapy because its such a big and therefore profitable market. Amylin has an advantage in being closer to approval/marketing and also in using a type of therapy with which the medical profession has had a lot of experience. I see a lot of hedging and glossoverlingua in the company press release and am concerned about that. Type 1 diabetes is only 10% of the market and this is not enough to make Amylin a priority investment for me. The clinical trials program seems unfocused and the results of the first trial are not statistically significant at 12 months for type 2 diabetes. Despite my doubts, I hope your right. : ) David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next